The Neurologist Who Rewrote the Rules of Multiple Sclerosis Treatment

National Multiple Sclerosis Society / American Academy of Neurology

In the early 1980s, a young German neurologist named Ludwig Kappos joined an interdisciplinary multiple sclerosis research group run by the Max Planck Society in Würzburg. At the time, there was almost nothing to offer patients. No disease-modifying therapies. No reliable way to measure whether a drug was working. No standardized tools for tracking how disability progressed. MS was a diagnosis that came with sympathy and steroids, and not much else.

Four decades later, more than twenty disease-modifying therapies are approved for MS. Clinicians can monitor disease activity with brain imaging in real time. Researchers can distinguish between disability caused by inflammatory relapses and disability that accumulates silently, without any relapse at all. And Ludwig Kappos's fingerprints are on nearly every part of that transformation.

On April 19, 2026, Kappos will receive the John Dystel Prize for Multiple Sclerosis Research at the American Academy of Neurology's annual meeting in Chicago. The award, given jointly by the AAN and the National MS Society, is one of the highest honors in the field. But the real story is not the prize. It is the distance between what MS looked like when Kappos started and what it looks like now -- and his role in closing that gap.

A disease with no yardstick

To understand Kappos's contribution, you have to understand a problem that plagued MS research for years: no one could agree on how to measure the disease.

John Kurtzke's Expanded Disability Status Scale, or EDSS, had existed since the 1980s as a way to rate neurological impairment. But the scale was applied inconsistently across clinics and trial sites. A score of 4.0 at one center might mean something different at another. That inconsistency was more than an academic nuisance. It meant clinical trials could produce conflicting results not because the drugs differed, but because the measurements did.

Kappos helped solve this by developing Neurostatus-EDSS, a rigorously standardized version of the scale with defined examination procedures and training requirements. It became the most widely used tool for measuring disability in MS clinical trials worldwide. That might sound like plumbing -- unglamorous infrastructure work -- but without reliable measurement, no trial result means anything. Kappos built the ruler that the entire field now uses.

He did something similar with imaging. Kappos was among the researchers who established magnetic resonance imaging (MRI) as a central tool for evaluating new treatments and monitoring disease activity, both in trials and in standard clinical care. Before MRI became routine in MS, clinicians were largely flying blind between relapses, unable to see the subclinical inflammation slowly eating away at the brain and spinal cord. Imaging changed that. It gave researchers eyes inside the disease.

The trial architect

Building measurement tools was only part of it. Kappos played a pivotal role in the clinical trials that established the safety and effectiveness of nearly every class of disease-modifying therapy now available to MS patients. That is an extraordinary claim, but it is backed by the sheer volume of his work: more than 850 peer-reviewed publications over the course of his career.

The drugs themselves tell the story of a field in motion. Early interferons and glatiramer acetate gave patients their first real options. Then came oral medications -- a leap in convenience and adherence. Then monoclonal antibodies targeting specific immune pathways, offering stronger suppression of disease activity. And finally, therapies that showed benefit in progressive forms of MS, a category that had resisted treatment for decades.

Kappos was involved in trials across these categories, not as a figurehead but as someone who shaped how the trials were designed, how outcomes were measured, and how results were interpreted. Amit Bar-Or, a previous Dystel Prize recipient and a leading MS researcher in his own right, put it plainly: Kappos provided "essential clinical and academic perspectives that have helped guide the development of multiple now-approved MS therapies."

That phrasing -- "guide the development" -- is worth pausing on. Drug development in MS is not a single experiment. It is a years-long process of phase I, II, and III trials, regulatory negotiation, and post-market surveillance. The people who shape that process at the design level have an outsized influence on which drugs make it to patients and how quickly they arrive.

The silent thief inside progression

If Kappos had stopped at trial design and measurement standardization, his legacy would already be secure. But some of his most consequential work came later, and it challenged a basic assumption about how MS works.

For years, the field operated on a relatively straightforward model: MS caused relapses (acute inflammatory attacks), and disability accumulated as a result of those relapses. Stop the relapses, the thinking went, and you stop the disability. Disease-modifying therapies were built around this logic, and they worked -- up to a point.

But clinicians kept seeing patients whose disability worsened even though their relapses were well controlled. Something else was going on. Kappos and his colleagues helped put a name and a framework on it: progression independent of relapse activity, or PIRA.

Their work demonstrated that across all traditional disease categories -- relapsing-remitting, secondary progressive, primary progressive -- many patients accumulate disability through mechanisms that operate independently of the inflammatory relapses that drugs were designed to suppress. This was not a minor refinement. It reshaped the field's understanding of what MS actually is.

PIRA suggested that MS is not one process but at least two: an inflammatory process that causes relapses, and a neurodegenerative process that grinds forward regardless. Treating one does not necessarily treat the other. That insight has profound implications for drug development, because it means an entire dimension of the disease has been undertreated -- and in many cases, unmeasured.

The concept is still being refined, and its therapeutic implications are still being worked out. But PIRA has already changed how researchers design trials, what endpoints they measure, and how they think about what "effective treatment" means for someone with MS.

Basel and beyond

Since moving to the University Hospital Basel in 1990, Kappos built what colleagues describe as one of the world's leading MS research programs. He served as Chair of Neurology at the University of Basel from 2008, and now leads the Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) as its CEO. The program merges advanced imaging, biomarker science, and comprehensive clinical evaluation in a way that few centers have managed to replicate.

Bar-Or called it "world-leading" and noted that it "sets the bar for how to merge cutting edge imaging and biomarker science with comprehensive clinical evaluations." Bruce Bebo, the National MS Society's Chief Research and Medical Affairs Officer, described Kappos as "one of the most influential leaders in modern MS research," adding that "few individuals have had such a broad and lasting impact on the field."

Perhaps as important as the research itself is what Kappos built around it. He has mentored more than fifteen clinician-scientists who now lead MS research and care programs across the globe. That kind of institutional legacy -- seeding the next generation with people trained in rigorous methodology and interdisciplinary thinking -- multiplies the impact of any single researcher's work.

What a career measures

Kappos received the 2025 Charcot Award from the MS International Federation, which recognizes a lifetime of achievement. The Dystel Prize follows less than a year later. He was nominated by Bar-Or, Stephen Hauser, and Xavier Montalban -- all previous Dystel recipients -- which gives the nomination the weight of peer recognition at the highest level.

In his own remarks, Kappos deflected credit toward collaborators, calling the prize "a strong motivator for our group to continue and expand on innovative and productive collaborations across disciplines and borders." That instinct -- toward collective effort rather than individual celebrity -- is consistent with a career spent building infrastructure rather than chasing headlines.

An estimated one million people in the United States live with MS. There is still no cure. But the distance between an MS diagnosis in 1982 and one in 2026 is vast: in available therapies, in diagnostic precision, in the basic scientific understanding of what the disease does and how it progresses. Ludwig Kappos did not close that distance alone. But he built many of the tools, trained many of the people, and asked many of the questions that made closing it possible.

The Dystel Prize lecture will be delivered at the AAN Annual Meeting in Chicago on April 19, 2026.